Mostrando 3 resultados de: 3
Filtros aplicados
Publisher
Multiple Sclerosis Journal(1)
Multiple Sclerosis and Related Disorders(1)
Neurology and Therapy(1)
Origen
scopus(3)
Coronavirus disease 2019 in Latin American patients with multiple sclerosis
OtherAbstract: Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particuPalabras claves:covid-19, Multiple Sclerosis, ocrelizumab, pandemic, rituximabAutores:Carcamo Rodriguez C., Carmisciano L., Ciampi E., Edgar Patricio Correa, Fragoso Y.D., Gomes S., Pimentel M.L.V., Ponzano M., Santos G.A.C., Schiavetti I., Sormani M.P., Steinberg J., Treviño-Frenk I., Vecino M.C.A., Vrech C., Winckler T.C.A.Fuentes:scopusTowards establishing MS prevalence in Latin America and the Caribbean
ReviewAbstract: A very high prevalence of multiple sclerosis (MS) has been reported in some Western European and NorPalabras claves:Caribbean, Environmental risk, epidemiology, ethnicity, Hispanic, latitude, Multiple Sclerosis, Native American Indian, SOUTH AMERICA, UV exposureAutores:Bartoloni L., Brooks J.B.B., Cabrera Gomez J.A., Cristiano E., Diaz De Bedoya V.H., Díaz V., Duran J.C., Fragoso Y.D., Gracia F., Grzesiuk A.K., Hackembruch J.H., Islas M.M.I., Ketzoian C.N., Melcon C.M., Melcon M.O., Oehninger C., Patricio Emilio Abad, Romero García K.M., Ruiz M.C., Soto A.Fuentes:scopusPractical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
OtherAbstract: Abstract: The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin AmePalabras claves:Alemtuzumab, Biological drugs, Biosimilar, Glatiramoids, Interferon beta, Multiple Sclerosis, Natalizumab, ocrelizumabAutores:Carcamo Rodriguez C., Carra A., Ciampi E., Duran Quiroz J.C., Edgar Patricio Correa, Fragoso Y.D., García J.R., Guerra C., Macias M.A., Novarro N., Oehninger Gatti C., Orozco G., Rodriguez V., Steinberg J., Vizcarra D.Fuentes:scopus